70 results on '"Dejima T"'
Search Results
2. Optical Activation of Erbium Doped Porous Silicon by Hydrogen Plasma Treatment
- Author
-
Dejima, T., Saito, R., Yugou, S., Isshiki, H., and Kimura, T.
- Published
- 1997
- Full Text
- View/download PDF
3. 256 - LIM-SH3 domain protein 1 promotes tumorgenesis in prostate cancer
- Author
-
Dejima, T., Ario, T., Nicholas, E., Peter, B., Masatoshi, E., Martin, G., and Chrisopher, O.
- Published
- 2018
- Full Text
- View/download PDF
4. 969 - Inhibition of LIM-SH3 domain protein 1 (LASP1) augments the anti-cancer effect of cisplatin in bladder cancer
- Author
-
Dejima, T., Takeuchi, A., Shiota, M., Black, P., Eto, M., Naito, S., Gleave, M., and Ong, C.
- Published
- 2017
- Full Text
- View/download PDF
5. 847 - Inhibition of semaphorin 3C augments the anti-cancer effect of sunitinib in renal cancer
- Author
-
Dejima, T., Takeuchi, A., Eto, M., Naito, S., Gleave, M., and Ong, C.
- Published
- 2017
- Full Text
- View/download PDF
6. Prepubertal angiotensin blockade exerts long-term therapeutic effect through sustained ATRAP activation in salt-sensitive hypertensive rats.
- Author
-
Dejima T, Tamura K, Wakui H, Maeda A, Ohsawa M, Kanaoka T, Haku S, Kengo A, Masuda S, Shigenaga A, Azuma K, Matsuda M, Yabana M, Hirose T, Uchino K, Kimura K, Nagashima Y, and Umemura S
- Published
- 2011
- Full Text
- View/download PDF
7. UP-3.015: The Significance of Urine NMP22 in the Screening of Urothelial Cancer (Comparison of ELISA and Immunochromatography Method)
- Author
-
Ikeda, H., Ishida, Y., Dejima, T., Nomura, M., and Sanefuji, H.
- Published
- 2009
- Full Text
- View/download PDF
8. EFFECTS OF ALISKIREN-BASED THERAPY ON AMBULATORY BLOOD PRESSURE PROFILE AND CENTRAL AORTIC PRESSURE IN UNTREATED PATIENTS WITH MILD-TO-MODERATE ESSENTIAL HYPERTENSION.
- Author
-
Kanaoka, T., Tamura, K., Wakui, H., Osawa, M., Yanagi, M., Haku, S., Maeda, A., Dejima, T., Azushima, K., Azuma, K., Toya, Y., and Umemura, S.
- Published
- 2011
- Full Text
- View/download PDF
9. DIFFERENTIAL EFFECTS BETWEEN ALISKIREN AND BENAZEPRIL WHEN USED IN COMBINATION WITH ANGIOTENSIN II RECEPTOR BLOCKER ON ALBUMINURIA AND CARDIAC HYPERTROPHY IN CHRONIC KIDNEY DISEASE PATIENTS WITH HYPERTENSION.
- Author
-
Ohsawa, M., Tamura, K., Azushima, K., Haku, S., Kanaoka, T., Maeda, A., Dejima, T., Wakui, H., Azuma, K., Toya, Y., and Umemura, S.
- Published
- 2011
- Full Text
- View/download PDF
10. GENE-SPECIFIC DISRUPTION OF ANGIOTENSIN II TYPE 1 RECEPTOR-ASSOCIATED PROTEIN REVEALS A NOVEL ROLE IN THE PATHOGENESIS OF METABOLIC SYNDROME.
- Author
-
Maeda, A., Tamura, K., Wakui, H., Dejima, T., Ohsawa, M., Kanaoka, T., Haku, S., Masuda, S., Azuma, K., Matsuda, M., Toya, Y., and Umemura, S.
- Published
- 2011
- Full Text
- View/download PDF
11. RENAL ENHANCEMENT OF AT1 RECEPTOR-ASSOCIATED PROTEIN PREVENTS SALT-INDUCED HYPERTENSION.
- Author
-
Tamura, K., Wakui, H., Tsurumi-Ikeya, Y., Dejima, T., Maeda, A., Ohsawa, M., Kanaoka, T., Oshikawa, J., Kobayashi, Y., Minegishi, S., Yoshida, S., Masuda, S., Azuma, K., Ishigami, T., and Umemura, S.
- Published
- 2011
- Full Text
- View/download PDF
12. PRE-PUBERTAL BLOCKADE OF ANGIOTENSIN II TYPE 1 RECEPTOR EXERTS LONG-TERM THERAPEUTIC EFFECTS THROUGH SUSTAINED ENHANCEMENT OF RENAL ATRAP EXPRESSION IN DAHL SALT-SENSITIVE HYPERTENSIVE RATS.
- Author
-
Dejima, T., Tamura, K., Wakui, H., Maeda, A., Ohsawa, M., Kanaoka, T., Haku, S., Masuda, S., Shigenaga, A., Azuma, K., Matsuda, M., Yabana, M., Uchino, K., and Umemura, S.
- Published
- 2011
- Full Text
- View/download PDF
13. RENAL FUNCTIONAL DETERIORATION DECREASES INTRARENAL EXPRESSION OF HUMAN ANGIOTENSIN RECEPTOR BINDING AND INHIBITORY MOLECULE.
- Author
-
Tamura, K., Wakui, H., Masuda, S., Dejima, T., Maeda, A., Kanaoka, T., Ohsawa, M., Haku, S., Azushima, K., Azuma, K., Ishigami, T., Toya, Y., and Umemura, S.
- Published
- 2011
- Full Text
- View/download PDF
14. 42 Targeting clusterin-associated proteins improve cellular sensitivity to taxane in prostate cancer.
- Author
-
Takeuchi, A., Shiota, M., Katsunori, T., Inokuchi, J., Kashiwagi, E., Dejima, T., Yokomizo, A., and Eto, M.
- Subjects
- *
CLUSTERIN , *TARGETED drug delivery , *TAXANES , *PROSTATE cancer treatment , *MEDICAL centers - Published
- 2016
- Full Text
- View/download PDF
15. Efficacy and safety of Vibegron for the treatment of residual overactive bladder symptoms after laser vaporization of the prostate: A single-center prospective randomized controlled trial (VAPOR TRIAL).
- Author
-
Seki N, Masaoka H, Song Y, Dejima T, Sato Y, and Maeda S
- Subjects
- Humans, Male, Aged, Prospective Studies, Prostatic Hyperplasia surgery, Prostatic Hyperplasia complications, Treatment Outcome, Aged, 80 and over, Pyrimidinones, Pyrrolidines, Urinary Bladder, Overactive etiology, Urinary Bladder, Overactive drug therapy, Laser Therapy methods, Laser Therapy adverse effects
- Abstract
Objectives: This study aimed to evaluate the efficacy and safety of Vibegron for the treatment of residual overactive bladder (OAB) symptoms after laser vaporization of the prostate (photo-selective vaporization of the prostate, contact laser vaporization of the prostate, and thulium laser vaporization)., Methods: This randomized, open-label, parallel-group, single-center superiority trial with a 12-week observation (jRCTs071190040) enrolled male patients with OAB aged 40 years or older who had undergone laser vaporization of the prostate for not less than 12 weeks and not more than 1 year earlier. Patients were allocated to receive Vibegron 50 mg once daily or follow-up without treatment for 12 weeks., Results: Forty-seven patients were enrolled between January 2020 and March 2023. The median age (interquartile range) was 75.5 (72.5-78.5) years for the Vibegron group and 76.5 (71.0-81.0) years for the control group. The intergroup difference in the mean change (95% confidence interval) in the 24-hour urinary frequency at 12 weeks after randomization was -3.66 (-4.99, -2.33), with a significant decrease for the Vibegron group. The Overactive Bladder Symptom Score, International Prostate Symptom Score, IPSS storage score, and Overactive Bladder Questionnaire score significantly improved for the Vibegron group. Voided volume per micturition also increased for the Vibegron group., Conclusions: The administration of 50 mg of Vibegron once daily for 12 weeks showed significant improvement compared with follow-up without treatment in bladder storage (OAB) symptoms after laser vaporization of the prostate for symptomatic benign prostatic hyperplasia., (© 2024 John Wiley & Sons Australia, Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
16. A prospective, single-center, randomized clinical trial to evaluate the efficacy of three types of laser vaporization surgeries using a 180-W GreenLight XPS laser, a 300-W diode laser, and a 200-W thulium laser for the treatment of benign prostatic hyperplasia.
- Author
-
Okada T, Koura M, Sumikawa R, Masaoka H, Song Y, Dejima T, and Seki N
- Subjects
- Humans, Lasers, Semiconductor therapeutic use, Male, Prospective Studies, Quality of Life, Thulium, Treatment Outcome, Volatilization, Laser Therapy methods, Prostatic Hyperplasia complications, Transurethral Resection of Prostate adverse effects, Transurethral Resection of Prostate methods
- Abstract
Objectives: This study aimed to compare the safety and efficacy of three different laser prostate vaporization surgeries, which were photoselective vaporization of the prostate (PVP), diode laser vaporization (DVP), and thulium laser vaporization (ThuVAP), for the treatment of benign prostatic hyperplasia (BPH) in a randomized clinical trial., Methods: A total of 71 consecutive patients with BPH were included; 23 patients were treated with PVP, 23 with DVP, and 25 with ThuVAP. Patients were evaluated with disease-related symptomatic questionnaires, Quality of Life (QOL) Index, and maximum urinary flow rate (Q
max ) for 12 months. Patients were monitored to record operation/vaporization time, 24-hour hemoglobin/sodium drop, length of catheterization/hospitalization, and perioperative/postoperative complications., Results: In all three groups, patients showed significant and comparable improvements in symptom scores, QOL Index, and Qmax during the 12-month follow-up period. The mean operation/vaporization time was equivalent across all three groups at 69/23 (PVP), 81/34 (DVP), and 76/32 minutes (ThuVAP), while the applied laser energy was lower for PVP at 157 kJ compared to the other two techniques (DVP at 358 kJ, ThuVAP at 240 kJ). The mean vaporization rates per unit energy were significantly different between the three groups (PVP 0.16, DVP 0.09, and ThuVAP 0.09 mL/kJ). There were no significant differences in the main safety profiles between the three groups., Conclusions: Our study demonstrated that these three types of laser surgeries are similar in terms of complications and outcomes, with excellent hemostasis and high patient satisfaction. It was suggested that sufficient tissue vaporization could be achieved using less energy through PVP surgery., (© 2022 John Wiley & Sons Australia, Ltd.)- Published
- 2022
- Full Text
- View/download PDF
17. GreenLight HPS laser 120 W vs diode laser 300 W vaporization of the prostate for the treatment of benign prostatic hyperplasia in Japanese patients: A prospective, single-center, randomized clinical trial.
- Author
-
Kobayashi T, Seki N, Song YH, and Dejima T
- Subjects
- Aged, Aged, 80 and over, Humans, Japan, Lasers, Semiconductor adverse effects, Lasers, Solid-State adverse effects, Male, Middle Aged, Prostate surgery, Treatment Outcome, Lasers, Semiconductor therapeutic use, Lasers, Solid-State therapeutic use, Prostatic Hyperplasia surgery
- Abstract
Objectives: This study aimed to compare the safety and efficacy of laser vaporization with 532 nm GreenLight High Performance System (HPS) laser 120 W (PVP) and 980 nm diode laser 300 W (CVP) for the treatment of benign prostatic hyperplasia (BPH) in a prospective, single-center, randomized clinical trial., Methods: A total of 153 consecutive patients with symptomatic BPH were included; 79 patients were treated with PVP and 74 with CVP. Patients were assessed preoperatively and at 3, 6, and 12 months postoperatively using the International Prostate Symptom Score, quality of life index, peak urinary flow rate, and postvoid residual urine volume. All perioperative and postoperative complications were noted., Results: There were significant and comparable improvements in each of the outcome variables over a follow-up period of 12 months in both groups. The mean operation/vaporization duration (minutes) was comparable at 74/38 (PVP) and 76/34 (CVP), whereas the mean applied laser energy was significantly higher with CVP than with PVP at 260 vs 195 (kJ), respectively. The mean vaporization rate (mL/min) was not significantly different between the two groups (0.53 PVP vs 0.56 CVP). Immediately after surgery, the rate of recatheterization for urinary retention was significantly higher with CVP than with PVP (17.6% vs 6.8%; P < 0.05)., Conclusions: Both laser systems provided comparable improvement in the subjective and objective parameters with excellent hemostatic properties. Although our results suggest that both procedures are useful treatment choices, further follow-up is needed to draw definitive conclusions regarding the most ideal laser for treating patients with symptomatic BPH., (© 2020 John Wiley & Sons Australia, Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
18. Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants.
- Author
-
Shiota M, Dejima T, Yamamoto Y, Takeuchi A, Imada K, Kashiwagi E, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, and Eto M
- Subjects
- Aged, Androgen Receptor Antagonists pharmacology, Androgen Receptor Antagonists therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Benzamides, Cell Line, Tumor, Disease-Free Survival, Gene Knockdown Techniques, Humans, Male, Nitriles, Phenylthiohydantoin analogs & derivatives, Phenylthiohydantoin pharmacology, Phenylthiohydantoin therapeutic use, Prostate pathology, Prostate-Specific Antigen blood, Prostatic Neoplasms, Castration-Resistant blood, Prostatic Neoplasms, Castration-Resistant genetics, Prostatic Neoplasms, Castration-Resistant mortality, RNA, Small Interfering metabolism, Receptors, Androgen metabolism, Signal Transduction drug effects, Signal Transduction genetics, Taxoids therapeutic use, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols pharmacology, Drug Resistance, Neoplasm genetics, Prostatic Neoplasms, Castration-Resistant drug therapy, Receptors, Androgen genetics, Taxoids pharmacology
- Abstract
Currently, the optimal sequential use of androgen receptor (AR) axis-targeted agents and taxane chemotherapies remains undetermined. We aimed to elucidate the resistance status between taxanes and enzalutamide, and the functional role of the AR axis. Enzalutamide-resistant 22Rv1 cells showed collateral resistance to taxanes, including docetaxel and cabazitaxel. However, taxane-resistant cells showed no collateral resistance to enzalutamide; taxane-resistant cells expressed comparable protein levels of full-length AR and AR variants. Knockdown of both full-length AR and AR variants rendered cells sensitive to taxanes, whereas knockdown of AR variants sensitized cells to enzalutamide, but not to taxanes. In contrast, overexpression of full-length AR rendered cells resistant to taxanes. Consistently, the prostate-specific antigen response and progression-free survival in docetaxel chemotherapy were worse in cases with prior use of ARAT agents compared with cases without. Collateral resistance to taxanes was evident after obtaining enzalutamide resistance, and aberrant AR signaling might be involved in taxane resistance., (© 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.)
- Published
- 2018
- Full Text
- View/download PDF
19. Time course of restenosis with "black hole" on intravascular ultrasound after implantation of platinum-chromium everolimus-eluting stent: Assessment using optical frequency-domain imaging.
- Author
-
Kikuchi S, Morita Y, Kanna M, Dejima T, Nakayama M, Okajima Y, Hibi K, Kimura K, and Tamura K
- Abstract
Management of in-stent restenosis (ISR) remains challenging even in the drug-eluting stent era. We report the case of a Japanese female with repeated ISR after primary percutaneous coronary intervention (PCI) for acute coronary syndrome. We observed ISR tissue with "black hole" on intravascular ultrasound, which appeared to be heterogeneous tissue on optical frequency-domain imaging (OFDI). Paclitaxel-coated balloon dilatation of the ISR lesion with "black hole" was ineffective. The morphological assessment of ISR tissue using OFDI might be important to treat ISR lesions by PCI. OFDI is a novel tool to observe the difference in the in-stent tissue characteristics. < Learning objective: In-stent restenosis (ISR) remains a clinical problem even in the drug-eluting stent (DES) era. The morphological assessment of ISR tissue using optical frequency-domain imaging (i.e. homogeneous, heterogeneous, and layered types) might be important to treat ISR lesions by percutaneous coronary intervention since the reaction to DES and drug-coating balloon seems to be different according to the in-stent tissue characteristics.>.
- Published
- 2018
- Full Text
- View/download PDF
20. The Association of Polymorphisms in the Gene Encoding Gonadotropin-Releasing Hormone with Serum Testosterone Level during Androgen Deprivation Therapy and Prognosis of Metastatic Prostate Cancer.
- Author
-
Shiota M, Fujimoto N, Takeuchi A, Kashiwagi E, Dejima T, Inokuchi J, Tatsugami K, Yokomizo A, Kajioka S, Uchiumi T, and Eto M
- Subjects
- Aged, Alleles, Disease Progression, Follow-Up Studies, Gonadotropin-Releasing Hormone genetics, Gonadotropin-Releasing Hormone metabolism, Humans, Male, Neoplasm Metastasis, Prognosis, Prostatic Neoplasms drug therapy, Prostatic Neoplasms secondary, Retrospective Studies, Treatment Outcome, Androgen Antagonists therapeutic use, DNA, Neoplasm genetics, Gonadotropin-Releasing Hormone analogs & derivatives, Polymorphism, Genetic, Prostatic Neoplasms genetics, Testosterone blood
- Abstract
Purpose: Serum testosterone suppression during androgen deprivation therapy has been reported to affect the efficacy of androgen deprivation therapy. However, the factors impacting hormonal variations during androgen deprivation therapy remain unclear. Therefore, in this study we investigated the significance of missense polymorphisms in the gene encoding GNRH in men treated with primary androgen deprivation therapy for metastatic prostate cancer., Materials and Methods: This study included 80 Japanese patients with metastatic prostate cancer with available serum testosterone levels during androgen deprivation therapy. We examined the association of GNRH1 (rs6185, S20W) and GNRH2 (rs6051545, A16V) gene polymorphisms with clinicopathological parameters, including serum testosterone levels during androgen deprivation therapy, as well as prognosis, including progression-free and overall survival., Results: The CT and CT/TT alleles in the GNRH2 gene (rs6051545) were associated with higher serum testosterone during androgen deprivation therapy compared with those of the CC allele. Consequently the CT alleles were associated with a higher risk of progression after adjustment for age and serum testosterone during androgen deprivation therapy (HR 1.73, 95% CI 1.00-3.00, p = 0.049)., Conclusions: Taken together these findings suggest that rs6051545 (GNRH2) genetic variation may result in inadequate suppression of serum testosterone during androgen deprivation therapy. This may lead to detrimental effects of androgen deprivation therapy on prognosis in men with metastatic prostate cancer., (Copyright © 2018 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
21. SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1.
- Author
-
Peacock JW, Takeuchi A, Hayashi N, Liu L, Tam KJ, Al Nakouzi N, Khazamipour N, Tombe T, Dejima T, Lee KC, Shiota M, Thaper D, Lee WC, Hui DH, Kuruma H, Ivanova L, Yenki P, Jiao IZ, Khosravi S, Mui AL, Fazli L, Zoubeidi A, Daugaard M, Gleave ME, and Ong CJ
- Subjects
- Animals, Cell Proliferation, Humans, Male, Mice, Prostatic Neoplasms, Castration-Resistant pathology, Semaphorins antagonists & inhibitors, Signal Transduction, Xenograft Model Antitumor Assays, Nerve Tissue Proteins metabolism, Prostatic Neoplasms, Castration-Resistant metabolism, Receptor Protein-Tyrosine Kinases metabolism, Receptors, Cell Surface metabolism, Semaphorins metabolism
- Abstract
Growth factor receptor tyrosine kinase (RTK) pathway activation is a key mechanism for mediating cancer growth, survival, and treatment resistance. Cognate ligands play crucial roles in autocrine or paracrine stimulation of these RTK pathways. Here, we show SEMA3C drives activation of multiple RTKs including EGFR, ErbB2, and MET in a cognate ligand-independent manner via Plexin B1. SEMA3C expression levels increase in castration-resistant prostate cancer (CRPC), where it functions to promote cancer cell growth and resistance to androgen receptor pathway inhibition. SEMA3C inhibition delays CRPC and enzalutamide-resistant progression. Plexin B1 sema domain-containing:Fc fusion proteins suppress RTK signaling and cell growth and inhibit CRPC progression of LNCaP xenografts post-castration in vivo SEMA3C inhibition represents a novel therapeutic strategy for treatment of advanced prostate cancer., (© 2018 The Authors. Published under the terms of the CC BY 4.0 license.)
- Published
- 2018
- Full Text
- View/download PDF
22. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
- Author
-
Obata H, Shiota M, Akitake N, Takeuchi A, Kashiwagi E, Dejima T, Kiyoshima K, Inokuchi J, Tatsugami K, and Eto M
- Subjects
- Adenocarcinoma mortality, Adenocarcinoma pathology, Aged, Androgen Antagonists adverse effects, Antineoplastic Agents, Hormonal adverse effects, Biopsy, Chemoradiotherapy adverse effects, Chemoradiotherapy mortality, Chemotherapy, Adjuvant, Chi-Square Distribution, Disease Progression, Disease-Free Survival, Humans, Japan, Kaplan-Meier Estimate, Male, Middle Aged, Multivariate Analysis, Neoplasm Grading, Proportional Hazards Models, Prostatectomy adverse effects, Prostatectomy mortality, Prostatic Neoplasms mortality, Prostatic Neoplasms pathology, Prostatic Neoplasms, Castration-Resistant mortality, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome, Adenocarcinoma therapy, Androgen Antagonists therapeutic use, Antineoplastic Agents, Hormonal therapeutic use, Chemoradiotherapy methods, Neoplasm Recurrence, Local, Prostatectomy methods, Prostatic Neoplasms therapy, Prostatic Neoplasms, Castration-Resistant pathology
- Abstract
Background/aim: Salvage androgen-deprivation therapy (ADT) is standard treatment for recurrent prostate cancer after curative therapy. However, the prognostic impact of different treatment modalities on the time to castration resistance remains unclear. In this study, we investigated the prognosis of men treated with salvage ADT after initial radical prostatectomy or radiotherapy for prostate cancer., Patients and Methods: Between 2000 and 2013, 149 Japanese men with recurrent prostate cancer who were initially treated with radical prostatectomy (n=95) or radiotherapy (n=54) and were subsequently treated with salvage ADT after disease recurrence were enrolled in this study. The prognostic significance of the curative treatment modality and clinicopathological findings were analyzed., Results: During a median follow-up period of 4.7 years after recurrence, castration-resistant progression was observed in 22 men. The 5-year progression-free survival, metastasis-free survival, cause-specific survival, and overall survival rates for all patients were 86.3%, 81.4%, 95.7%, and 94.5%, respectively. Multivariate analysis identified the biopsy Gleason score at initial diagnosis and the initial curative treatment modality as significant predictors of castration resistance., Conclusion: This study showed that low biopsy Gleason score (≤7) at diagnosis and radical prostatectomy as the curative treatment may be favorable prognostic factors for treatment with salvage ADT., (Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
23. Possible combinatorial effects of current smoking and alcohol intake on chronic kidney disease in a Japanese nationwide cross-sectional survey.
- Author
-
Tamura K, Dejima T, Morita Y, Hirade S, and Wakui H
- Subjects
- Adult, Alcohol Drinking, Alcoholism complications, Cross-Sectional Studies, Female, Humans, Japan epidemiology, Male, Middle Aged, Renal Insufficiency, Chronic etiology, Risk Factors, Surveys and Questionnaires, Alcoholism epidemiology, Renal Insufficiency, Chronic epidemiology, Smoking adverse effects, Smoking epidemiology
- Published
- 2017
- Full Text
- View/download PDF
24. The Differential Impact of Body Mass Index and the Feature of Metabolic Syndrome on Oncological Outcomes Following Different Surgical Procedures in Japanese Men with Prostate Cancer.
- Author
-
Shiota M, Takeuchi A, Sugimoto M, Kashiwagi E, Dejima T, Kiyoshima K, Inokuchi J, Tatsugami K, Yokomizo A, and Eto M
- Subjects
- Blood Loss, Surgical, Disease-Free Survival, Dyslipidemias epidemiology, Humans, Japan epidemiology, Laparoscopy, Lymphatic Metastasis, Male, Neoplasm Grading, Neoplasm Recurrence, Local blood, Operative Time, Prostate-Specific Antigen blood, Prostatic Neoplasms blood, Prostatic Neoplasms pathology, Risk Factors, Body Mass Index, Metabolic Syndrome epidemiology, Neoplasm Recurrence, Local epidemiology, Overweight epidemiology, Prostatectomy methods, Prostatic Neoplasms mortality, Prostatic Neoplasms surgery
- Abstract
Purpose: This study aimed to examine the differential impact of body mass index and the feature of metabolic syndrome (MetS; obesity, hypertension, diabetes mellitus, and dyslipidemia) on biochemical recurrence (BCR) following radical prostatectomy (RP) treatment for prostate cancer using different surgical procedures., Methods: This study included 283 Japanese patients with clinically localized prostate cancer who were treated with RP between 2008 and 2012. The prognostic significance of overweight and the feature of MetS were analyzed according to surgical procedures., Results: BCR occurred in 68/283 (24.0%) men. Overweight and the feature of MetS were predictors of BCR in patients who had undergone open RP (ORP), but not in those treated with laparoscopic surgery. Multivariate analyses incorporating preoperative and postoperative risk factors revealed that overweight and the feature of MetS were independent BCR risk factors when treated with ORP., Conclusions: In Japanese men, overweight and the feature of MetS were associated with worse outcomes following RP, particularly ORP, compared with those following laparoscopic surgery. These results suggest that laparoscopic surgery can overcome the surgical challenges associated with abdominal obesity.
- Published
- 2017
- Full Text
- View/download PDF
25. Protein kinase C regulates Twist1 expression via NF-κB in prostate cancer.
- Author
-
Shiota M, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Inokuchi J, Tatsugami K, Uchiumi T, and Eto M
- Subjects
- Androgen Antagonists pharmacology, Benzamides, Cell Line, Tumor, Humans, Male, NF-kappa B genetics, Nitriles, Nuclear Proteins genetics, Phenylthiohydantoin analogs & derivatives, Phenylthiohydantoin pharmacology, Prostatic Neoplasms, Castration-Resistant genetics, Protein Kinase C-epsilon genetics, Receptors, Androgen genetics, Transcription Factor RelA genetics, Transcription Factor RelA metabolism, Twist-Related Protein 1 genetics, NF-kappa B metabolism, Nuclear Proteins metabolism, Prostatic Neoplasms, Castration-Resistant metabolism, Protein Kinase C-epsilon metabolism, Twist-Related Protein 1 metabolism
- Abstract
The progression of prostate cancer to metastatic and castration-resistant disease represents a critical step. We previously showed that protein kinase C (PKC) activation followed by Twist1 and androgen receptor (AR) induction played a critical role in castration resistance, but the precise molecular mechanism remains unknown. This study aimed to elucidate the relevant molecular mechanism, focusing on NF-κB transcription factor. We examined the activity of NF-κB after PKC inhibition, and the expression of Twist1 and AR after inhibition of NF-κB in human prostate cancer cells. We also investigated the status of PKC/NF-κB after inhibition of AR signaling in cells resistant to hormonal therapy. As a result, inhibition of PKC signaling using knockdown and small-molecule inhibition of PKC suppressed RelA activity, while blocking NF-κB suppressed Twist1 and AR expression. Conversely, inhibition of AR signaling by androgen depletion and the novel antiandrogen enzalutamide induced PKC and RelA activation, resulting in Twist1/AR induction at the transcript level. Moreover, inhibition of NF-κB signaling prevented enzalutamide-induced Twist1 and AR induction. Finally, NF-κB was activated in both castration-resistant and enzalutamide-resistant cells. In conclusion, NF-κB signaling was responsible for Twist1 upregulation by PKC in response to AR inhibition, resulting in aberrant activation of AR. NF-κB signaling thus appears to play a critical role in promoting both castration resistance and enzalutamide resistance in PKC/Twist1 signaling in prostate cancer., (© 2017 Society for Endocrinology.)
- Published
- 2017
- Full Text
- View/download PDF
26. Suppression of LIM and SH3 Domain Protein 1 (LASP1) Negatively Regulated by Androgen Receptor Delays Castration Resistant Prostate Cancer Progression.
- Author
-
Dejima T, Imada K, Takeuchi A, Shiota M, Leong J, Tombe T, Tam K, Fazli L, Naito S, Gleave ME, and Ong CJ
- Subjects
- Adaptor Proteins, Signal Transducing genetics, Androgen Antagonists pharmacology, Androgen Antagonists therapeutic use, Animals, Cytoskeletal Proteins genetics, Gene Knockdown Techniques methods, Humans, LIM Domain Proteins genetics, Male, Mice, Mice, Nude, Prostatic Neoplasms, Castration-Resistant drug therapy, Receptors, Androgen genetics, Adaptor Proteins, Signal Transducing antagonists & inhibitors, Adaptor Proteins, Signal Transducing biosynthesis, Cytoskeletal Proteins antagonists & inhibitors, Cytoskeletal Proteins biosynthesis, Disease Progression, LIM Domain Proteins antagonists & inhibitors, LIM Domain Proteins biosynthesis, Prostatic Neoplasms, Castration-Resistant metabolism, Receptors, Androgen biosynthesis
- Abstract
Background: LIM and SH3 domain protein 1 (LASP1) has been implicated in several human malignancies and has been shown to predict PSA recurrence in prostate cancer. However, the anti-tumor effect of LASP1 knockdown and the association between LASP1 and the androgen receptor (AR) remains unclear. The aim of this study is to clarify the significance of LASP1 as a target for prostate cancer, and to test the effect of silencing LASP1 in vivo using antisense oligonucleotides (ASO)., Methods: A tissue microarray (TMA) was performed to characterize the differences in LASP1 expression in prostate cancer treated after hormone deprivation therapy. Flow cytometry was used to analyze cell cycle. We designed LASP1 ASO for knockdown of LASP1 in vivo studies., Results: The expression of LASP1 in TMA was increased after androgen ablation and persisted in castration resistant prostate cancer (CRPC). Also in TMA, compared with LNCaP cell, LASP1 expression is elevated in CRPC cell lines (C4-2 and VehA cells). Interestingly, suppression of AR elevated LASP1 expression conversely, AR activation decreased LASP1 expression. Silencing of LASP1 reduced cell growth through G1 arrest which was accompanied by a decrease of cyclin D1. Forced overexpression of LASP1 promoted cell cycle and induced cell growth which was accompanied by an increase of cyclin D1. Systemic administration of LASP1 ASO with athymic mice significantly inhibited tumor growth in CRPC xenografts., Conclusions: These results indicate that LASP1 is negatively regulated by AR at the transcriptional level and promotes tumor growth through induction of cell cycle, ultimately suggesting that LASP1 may be a potential target in prostate cancer treatment. Prostate 77:309-320, 2017. © 2016 Wiley Periodicals, Inc., (© 2016 Wiley Periodicals, Inc.)
- Published
- 2017
- Full Text
- View/download PDF
27. Suppressed Recurrent Bladder Cancer after Androgen Suppression with Androgen Deprivation Therapy or 5α-Reductase Inhibitor.
- Author
-
Shiota M, Kiyoshima K, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Takahashi R, Inokuchi J, Tatsugami K, and Eto M
- Subjects
- 5-alpha Reductase Inhibitors adverse effects, Administration, Intravesical, Aged, Androgen Antagonists adverse effects, Antineoplastic Agents administration & dosage, Disease Progression, Humans, Japan, Male, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local pathology, Prostatic Hyperplasia drug therapy, Prostatic Neoplasms drug therapy, Retrospective Studies, Risk Factors, Urinary Bladder pathology, Urinary Bladder Neoplasms drug therapy, 5-alpha Reductase Inhibitors therapeutic use, Androgen Antagonists therapeutic use, Neoplasm Recurrence, Local epidemiology, Urinary Bladder Neoplasms pathology
- Abstract
Purpose: We determined whether intravesical recurrence is affected by inhibition of androgen signaling among men with nonmuscle invasive bladder cancer., Materials and Methods: We examined the intravesical recurrence rate among men treated with or without androgen suppression therapy by androgen deprivation therapy for prostate cancer or 5α-reductase inhibitor dutasteride for benign prostatic hyperplasia., Results: We studied 228 men, including 32 with and 196 without androgen suppression therapy. During a median followup of 3.6 and 3.0 years intravesical recurrence developed in 4 (12.5%) and 59 men (30.1%) with and without androgen suppression therapy, respectively. On multivariate analysis multiple tumors (HR 1.82, p = 0.027), a large tumor (HR 2.13, p = 0.043) and ever smoking (HR 2.45, p = 0.020) as well as the presence of androgen suppression therapy (HR 0.36, p = 0.024) were independent risk factors for intravesical recurrence. Notably, tumor progressed to muscle invasive bladder cancer in 6 men (3.1%) without androgen suppression therapy. No man with androgen suppression therapy progressed to muscle invasive bladder cancer., Conclusions: Our study suggests the possibility of androgen suppression therapy as prophylaxis for intravesical recurrence of bladder cancer. Further explorations are warranted of the prophylactic effect of androgen suppression therapy on bladder cancer pathogenesis., (Copyright © 2017 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
28. Antitumor activity of recombinant Bacille Calmette-Guérin secreting interleukin-15-Ag85B fusion protein against bladder cancer.
- Author
-
Takeuchi A, Eto M, Tatsugami K, Shiota M, Yamada H, Kamiryo Y, Dejima T, Kashiwagi E, Kiyoshima K, Inokuchi J, Takahashi R, Yokomizo A, Ohara N, and Yoshikai Y
- Subjects
- Acyltransferases genetics, Animals, Antigens, Bacterial genetics, Bacterial Proteins genetics, Cell Movement drug effects, Female, Genetic Engineering, Humans, Immunity, Interleukin-15 genetics, Lymphocyte Depletion, Mice, Mice, Inbred C57BL, Mycobacterium bovis genetics, Recombinant Fusion Proteins genetics, Urinary Bladder Neoplasms immunology, Immunotherapy methods, Interleukin-15 metabolism, Mycobacterium bovis immunology, Neutrophils physiology, Recombinant Fusion Proteins therapeutic use, Urinary Bladder Neoplasms therapy
- Abstract
Mycobacterium bovis Bacillus Calmette-Guérin (BCG) is used for the treatment of bladder cancer. The recruitment of neutrophlis to the bladder after BCG instillation exerts anti-tumor activity against bladder tumor. We have recently demonstrated that interleukin (IL)-17A produced by γδ T cells played a role in the recruitment of neutrophlis to the bladder after BCG instillation. IL-15 is known to play an important role in neutrophil migration during inflammation. We previously constructed a recombinant BCG strain expressing the fusion protein of IL-15 and Ag85B (BCG-IL-15) for prevention of Mycobacterium tuberculosis infection. Here we compared the efficacy of the BCG-IL-15 in protection against bladder cancer with that of rBCG-Ag85B (BCG). Six-week-old female C57BL/6 mice were inoculated with MB49 bladder tumor cells in the bladder and subsequently intravesically inoculated with BCG or BCG-IL-15. BCG-IL-15 treatment significantly prolonged survival of mice inoculated with bladder cancer cells compared with BCG treatment. Infiltration of neutrophils was significantly elevated in BCGB-IL-15 treated mice accompanied by increased chemokines (MIP-2 and MIP-1α) in the bladder. Thus, BCG-IL-15 exerted additive effect on Infiltration of neutrophils in the bladder. BCG-IL-15 may be a promising drug for non-muscle invasive bladder cancer., (Copyright © 2016 Elsevier B.V. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
29. Prognostic Impact of Serum Testosterone and Body Mass Index Before Androgen-deprivation Therapy in Metastatic Prostate Cancer.
- Author
-
Shiota M, Takeuchi A, Sugimoto M, Kashiwagi E, Dejima T, Kiyoshima K, Inokuchi J, Tatsugami K, and Yokomizo A
- Subjects
- Aged, Aged, 80 and over, Humans, Male, Neoplasm Metastasis, Orchiectomy, Prognosis, Prostatic Neoplasms pathology, Prostatic Neoplasms therapy, Survival Analysis, Androgen Antagonists therapeutic use, Body Mass Index, Gonadotropin-Releasing Hormone agonists, Prostatic Neoplasms diagnosis, Testosterone blood
- Abstract
Aim: Although the impact of testosterone or obesity on the efficacy of androgen-deprivation therapy (ADT) has been reported, there exist few comprehensive analyses on the impact of these factors on ADT outcome. Therefore, in the present study, we investigated the relationship between serum testosterone or body mass index (BMI) and prognosis among men treated with primary ADT for metastatic prostate cancer., Patients and Methods: The study included fifty-six Japanese patients with prostate cancer treated at our Institution from 2000 through 2012. The relationship between serum testosterone or BMI and progression-free survival, cancer-specific survival, and overall survival among men with metastatic prostate cancer treated with primary ADT was examined., Results: The median of serum testosterone and BMI were 397 ng/dl (interquartile range (IQR), 278-464 ng/dl) and 21.9 kg/m(2) (IQR, 19.2-23.6 kg/m(2)), respectively. Median progression-free survival, cancer-specific survival, and overall survival were 23.2 months, 68.9 months, and 68.1 months, respectively. Among clinicopathological parameters, the lowest-quartile group of serum testosterone level was a significant predictor of poor cancer-specific survival and overall survival as well as survival from castration resistance. However, BMI was not associated with prognosis., Conclusion: Serum testosterone level, but not obesity, is a prognostic factor for outcome including survival after getting castration-resistant prostate cancer in men with metastatic prostate cancer having undergone primary ADT., (Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)
- Published
- 2015
30. Low Serum Testosterone But Not Obesity Predicts High Gleason Score at Biopsy Diagnosed as Prostate Cancer in Patients with Serum PSA Lower than 20 ng/ml.
- Author
-
Shiota M, Takeuchi A, Sugimoto M, Dejima T, Kashiwagi E, Kiyoshima K, Inokuchi J, Tatsugami K, and Yokomizo A
- Subjects
- Aged, Body Mass Index, Follow-Up Studies, Humans, Male, Middle Aged, Multivariate Analysis, Neoplasm Grading, Neoplasm Staging, Prognosis, Prostatic Neoplasms blood, Prostatic Neoplasms surgery, Risk Assessment, Biomarkers, Tumor blood, Obesity physiopathology, Prostate-Specific Antigen blood, Prostatic Neoplasms diagnosis, Testosterone blood
- Abstract
Background/aim: The impact of testosterone or obesity on the pathological grade of prostate cancer remains controversial. Therefore, in this study, we investigated the relationship of serum testosterone and body mass index (BMI) to Gleason score at biopsy., Patients and Methods: This study included 128 Japanese patients diagnosed with prostate cancer from 2000 through 2012 whose serum testosterone level and BMI were measured before treatment. Associations between clinical parameters, including pre-treatment serum testosterone level and BMI, and Gleason score at biopsy were examined., Results: The median serum testosterone and BMI were 434 ng/dl (interquartile range=362-542 ng/dl) and 23.5 kg/m(2) (interquartile range=21.7-25.4 kg/m(2)), respectively. Gleason score at biopsy was <7, 7 and >7 for 58 patients (45.3%), 52 patients (40.6%) and 18 patients (14.1%), respectively. On univariate analysis, positive finding at digital rectal examination (DRE), high prostate-specific antigen level at diagnosis and low serum testosterone level, but not BMI, were correlated with high Gleason score at biopsy. Multivariate analysis identified positive finding at DRE and low serum testosterone level as significant predictors of a high Gleason score at prostate biopsy. By combining these parameters, the predictive ability of a high Gleason score was improved., Conclusion: This study showed that positive finding at DRE and a low pre-treatment serum testosterone level, but not obesity, may be factors predictive of aggressive prostate cancer, indicating the diagnostic value of serum testosterone, as well as DRE findings, in risk assessment., (Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)
- Published
- 2015
31. Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer.
- Author
-
Hayashi T, Seiler R, Oo HZ, Jäger W, Moskalev I, Awrey S, Dejima T, Todenhöfer T, Li N, Fazli L, Matsubara A, and Black PC
- Subjects
- Ado-Trastuzumab Emtansine, Animals, Apoptosis, Disease Models, Animal, Female, Gene Expression Regulation, Neoplastic, Humans, Male, Maytansine pharmacology, Mice, Tumor Cells, Cultured, Antibodies, Monoclonal, Humanized pharmacology, Antineoplastic Agents pharmacology, Maytansine analogs & derivatives, Receptor, ErbB-2 biosynthesis, Receptor, ErbB-2 drug effects, Trastuzumab pharmacology, Urinary Bladder Neoplasms metabolism
- Abstract
Purpose: Systemic therapy for advanced bladder cancer has not changed substantially in more than 2 decades and mortality rates remain high. The recognition of HER2 over expression in bladder cancer has made HER2 a promising therapeutic target. T-DM1, a new drug consisting of the HER2 antibody trastuzumab conjugated with a cytotoxic agent, has been shown in breast cancer to be superior to trastuzumab. We tested T-DM1 in preclinical models of bladder cancer., Materials and Methods: We evaluated the effect of T-DM1 compared to trastuzumab in different in vitro and in vivo models of HER2 over expressing bladder cancer., Results: RT4V6 was the highest HER2 expressing bladder cancer cell line and it showed higher growth inhibition with T-DM1 compared to trastuzumab. T-DM1 but not trastuzumab induced apoptosis of RT4V6 cells after G2/M arrest on cell cycle analysis. HER2 expression was higher in cell lines with acquired cisplatin resistance compared to the corresponding parental cell lines. Resistant cells showed higher sensitivity to T-DM1 by the induction of apoptosis. In addition, cells cultured in anchorage independent conditions increased HER2 expression compared to cells cultured in adherent conditions and T-DM1 significantly inhibited colony formation in soft agar compared to trastuzumab. In an orthotopic bladder cancer xenograft model tumor growth of cisplatin resistant RT112 was significantly inhibited by T-DM1 via the induction of apoptosis compared to treatment with control IgG or trastuzumab., Conclusions: T-DM1 has promising antitumor effects in preclinical models of HER2 over expressing bladder cancer., (Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
32. Effects of the oriental herbal medicine Bofu-tsusho-san in obesity hypertension: a multicenter, randomized, parallel-group controlled trial (ATH-D-14-01021.R2).
- Author
-
Azushima K, Tamura K, Haku S, Wakui H, Kanaoka T, Ohsawa M, Uneda K, Kobayashi R, Ohki K, Dejima T, Maeda A, Hashimoto T, Oshikawa J, Kobayashi Y, Nomura K, Azushima C, Takeshita Y, Fujino R, Uchida K, Shibuya K, Ando D, Tokita Y, Fujikawa T, Toya Y, and Umemura S
- Subjects
- Aged, Antihypertensive Agents adverse effects, Blood Pressure Monitoring, Ambulatory, Drug Therapy, Combination, Drugs, Chinese Herbal adverse effects, Female, Humans, Hypertension diagnosis, Hypertension etiology, Hypertension physiopathology, Japan, Male, Middle Aged, Phytotherapy, Plants, Medicinal, Prospective Studies, Time Factors, Treatment Outcome, Antihypertensive Agents therapeutic use, Blood Pressure drug effects, Drugs, Chinese Herbal therapeutic use, Hypertension drug therapy, Obesity complications
- Abstract
Objective: There is no clinical evidence that supports the benefit of integrative medicine, defined as combination therapy of oriental and western medicine, on obesity-related hypertension. This study evaluates the efficacy of Bofu-tsusho-san (BOF), an oriental herbal medicine, on the ambulatory blood pressure (BP) profile in hypertensive patients with obesity., Methods: The study design was a multicenter, randomized, open-label, parallel-group controlled trial in 107 hypertensive patients with obesity. Participants were randomly assigned to receive either the conventional control therapy or BOF add-on therapy. In both groups antihypertensive therapy was aimed at achieving the target clinic BP. The primary outcome was change in the ambulatory BP profile from baseline to 24 weeks after randomization., Results: Daytime systolic BP variability, an important parameter of ambulatory BP profile, was decreased in the BOF group, and the difference in the changes in daytime systolic BP variability was significant between the BOF and control group (Control vs BOF; the change from baseline in daytime systolic BP variability, 1.0±3.3 vs -1.0±3.3%; p=0.006)., Conclusion: The BOF add-on therapy effectively improved the ambulatory BP variability. This is the first report suggesting that an integrative medicine approach may exert favorable effects on obesity-related hypertension compared with conventional pharmaceutical treatment., Clinical Trial Registration: UMIN000003878., (Copyright © 2015 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
33. Renal tubule angiotensin II type 1 receptor-associated protein promotes natriuresis and inhibits salt-sensitive blood pressure elevation.
- Author
-
Wakui H, Uneda K, Tamura K, Ohsawa M, Azushima K, Kobayashi R, Ohki K, Dejima T, Kanaoka T, Tsurumi-Ikeya Y, Matsuda M, Haruhara K, Nishiyama A, Yabana M, Fujikawa T, Yamashita A, and Umemura S
- Subjects
- Adaptor Proteins, Signal Transducing genetics, Amiloride pharmacology, Angiotensin II metabolism, Animals, Biomarkers blood, Cell Membrane metabolism, Disease Models, Animal, Epithelial Sodium Channel Blockers pharmacology, Epithelial Sodium Channels drug effects, Epithelial Sodium Channels metabolism, Hypertension genetics, Hypertension metabolism, Hypertension physiopathology, Kidney Tubules, Distal drug effects, Kidney Tubules, Distal physiopathology, Mice, Inbred C57BL, Mice, Transgenic, Receptor, Angiotensin, Type 1 metabolism, Renin-Angiotensin System, Time Factors, Adaptor Proteins, Signal Transducing metabolism, Blood Pressure drug effects, Hypertension prevention & control, Kidney Tubules, Distal metabolism, Natriuresis drug effects, Sodium Chloride, Dietary
- Abstract
Background: Angiotensin II type 1 receptor (AT1R)-associated protein (ATRAP; Agtrap gene) promotes AT1R internalization along with suppression of pathological AT1R activation. In this study, we examined whether enhancement of ATRAP in the renal distal tubules affects sodium handling and blood pressure regulation in response to high salt (HS) loading, using ATRAP transgenic mice on a salt-sensitive C57BL/6J background., Methods and Results: Renal ATRAP transgenic (rATRAP-Tg) mice, which exhibit renal tubule-dominant ATRAP enhancement, and their wild-type littermate C57BL/6J mice on a normal salt diet (0.3% NaCl) at baseline were subjected to dietary HS loading (4% NaCl) for 7 days. In rATRAP-Tg mice, the dietary HS loading-mediated blood pressure elevation was suppressed compared with wild-type mice, despite similar baseline blood pressure. Although renal angiotensin II level was comparable in rATRAP-Tg and wild-type mice with and without HS loading, urinary sodium excretion in response to HS loading was significantly enhanced in the rATRAP-Tg mice. In addition, functional transport activity of the amiloride-sensitive epithelial Na(+) channel was significantly decreased under saline volume-expanded conditions in rATRAP-Tg mice compared with wild-type mice, without any evident change in epithelial Na(+) channel protein expression. Plasma membrane AT1R expression in the kidney of rATRAP-Tg mice was decreased compared with wild-type mice., Conclusions: These results demonstrated that distal tubule-dominant enhancement of ATRAP inhibits pathological renal sodium reabsorption and blood pressure elevation in response to HS loading. The findings suggest that ATRAP-mediated modulation of sodium handling in renal distal tubules could be a target of interest in salt-sensitive blood pressure regulation., (© 2015 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.)
- Published
- 2015
- Full Text
- View/download PDF
34. Renal cancer treatment with recipient lymphocyte infusion enhanced the antitumor effect of nonmyeloablative allogeneic stem cell transplantation.
- Author
-
Takeuchi A, Eto M, Tatsugami K, Yamada H, Yokomizo A, Shiota M, Itsumi M, Inokuchi J, Kiyoshima K, Dejima T, Imada K, Naito S, and Yoshikai Y
- Subjects
- Allografts, Animals, Cell Line, Tumor, Female, Mice, Mice, Inbred BALB C, Mice, Inbred DBA, Neoplasm Metastasis, Graft vs Host Disease immunology, Graft vs Host Disease pathology, Graft vs Host Disease therapy, Kidney Neoplasms immunology, Kidney Neoplasms pathology, Kidney Neoplasms therapy, Lymphocyte Transfusion, Stem Cell Transplantation
- Abstract
Background: Nonmyeloablative allogeneic stem cell transplantation (SCT) is an option for the treatment of metastatic renal cancer. Mature donor T cells cause graft versus-host disease (GVHD) although they are also the main mediators of the beneficial graft-versus-tumor (GVT) activity associated with this treatment. Hence, the segregation of GVT activity from GVHD is an important challenge in managing the clinical course of treatment. We previously reported a series of studies regarding the allograft tolerance induced by allogeneic spleen cells (with bone marrow cells) and cyclophosphamide in mice., Methods: The aim of the present study was to modify the cyclophosphamide-using cell therapy to reduce the risk of GVHD while preserving the antitumor activity against RENCA, a murine carcinogen-induced renal cell carcinoma with recipient lymphocyte infusion (RLI)., Results: Regarding the in vivo antitumor effect, there was a significant difference between RLI and no lymphocyte infusion after the cyclophosphamide treatment, whereas the histologic findings of the small intestine showed that the cyclophosphamide-using cell therapy with RLI decreased the risk of GVHD as compared with donor lymphocyte infusion. In addition, the acquired immunity against RENCA was clearly observed in RLI-treated mice., Conclusions: Our results show that RLI during cyclophosphamide-using nonmyeloablative cell therapy can dissociate GVT effects from GVHD by reducing the risk of GVHD. We considered that this was the first report to provide the evidence of nonmyeloablative allogeneic SCT with RLI for the treatment of renal cell carcinoma which never induce complete chimerism., (Copyright © 2014 Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
35. Deletion of the angiotensin II type 1 receptor-associated protein enhances renal sodium reabsorption and exacerbates angiotensin II-mediated hypertension.
- Author
-
Ohsawa M, Tamura K, Wakui H, Maeda A, Dejima T, Kanaoka T, Azushima K, Uneda K, Tsurumi-Ikeya Y, Kobayashi R, Matsuda M, Uchida S, Toya Y, Kobori H, Nishiyama A, Yamashita A, Ishikawa Y, and Umemura S
- Subjects
- Adaptor Proteins, Signal Transducing deficiency, Adaptor Proteins, Signal Transducing metabolism, Aldosterone blood, Aldosterone urine, Angiotensinogen metabolism, Animals, Blood Pressure drug effects, Blood Pressure genetics, Epithelial Sodium Channels drug effects, Gene Deletion, Hydrogen-Ion Concentration, Hypertension chemically induced, Kidney Tubules, Distal metabolism, Kidney Tubules, Proximal metabolism, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, RNA, Messenger metabolism, Receptor, Angiotensin, Type 1 genetics, Receptor, Angiotensin, Type 1 metabolism, Renal Reabsorption genetics, Sodium-Hydrogen Exchanger 3, Sodium-Hydrogen Exchangers metabolism, Urinalysis, Adaptor Proteins, Signal Transducing genetics, Angiotensin II pharmacology, Hypertension genetics, Renal Reabsorption drug effects, Sodium metabolism, Vasoconstrictor Agents pharmacology
- Abstract
Angiotensin II type 1 receptor (AT1R)-associated protein (ATRAP) promotes AT1R internalization along with suppression of pathological activation of tissue AT1R signaling. However, the functional significance of ATRAP in renal sodium handling and blood pressure regulation under pathological stimuli is not fully resolved. Here we show the blood pressure of mice with a gene-targeted disruption of ATRAP was comparable to that of wild-type mice at baseline. However, in ATRAP-knockout mice, angiotensin II-induced hypertension was exacerbated and the extent of positive sodium balance was increased by angiotensin II. Renal expression of the sodium-proton antiporter 3, a major sodium transporter in the proximal tubules, urinary pH, renal angiotensinogen production, and angiotensin II content was unaffected. Stimulation of the renal expression and activity of the epithelial sodium channel (ENaC), a major sodium transporter in the distal tubules, was significantly enhanced by chronic angiotensin II infusion. The circulating and urinary aldosterone levels were comparable. The blood pressure response and renal ENaC expression by aldosterone were not affected. Thus, ATRAP deficiency exacerbated angiotensin II-mediated hypertension by pathological activation of renal tubular AT1R by angiotensin II. This directly stimulates ENaC in the distal tubules and enhances sodium retention in an aldosterone-independent manner.
- Published
- 2014
- Full Text
- View/download PDF
36. PMA induces androgen receptor downregulation and cellular apoptosis in prostate cancer cells.
- Author
-
Itsumi M, Shiota M, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Inokuchi J, Tatsugami K, Uchiumi T, and Naito S
- Subjects
- Androgen Receptor Antagonists pharmacology, Antineoplastic Agents pharmacology, Apoptosis drug effects, Benzamides, Cell Line, Tumor, Down-Regulation drug effects, Drug Resistance, Neoplasm, E2F1 Transcription Factor antagonists & inhibitors, E2F1 Transcription Factor genetics, E2F1 Transcription Factor metabolism, Gene Knockdown Techniques, Humans, MAP Kinase Signaling System drug effects, Male, Nitriles, Phenylthiohydantoin analogs & derivatives, Phenylthiohydantoin pharmacology, Prostatic Neoplasms pathology, Prostatic Neoplasms, Castration-Resistant drug therapy, Prostatic Neoplasms, Castration-Resistant metabolism, Prostatic Neoplasms, Castration-Resistant pathology, Protein Kinase C metabolism, Signal Transduction drug effects, Tumor Suppressor Protein p53 antagonists & inhibitors, Tumor Suppressor Protein p53 genetics, Tumor Suppressor Protein p53 metabolism, Prostatic Neoplasms drug therapy, Prostatic Neoplasms metabolism, Receptors, Androgen metabolism, Tetradecanoylphorbol Acetate pharmacology
- Abstract
Phorbol 12-myristate 13-acetate (PMA) induces cellular apoptosis in prostate cancer cells, the growth of which is governed by androgen/androgen receptor (AR) signaling, but the mechanism by which PMA exerts this effect remains unknown. Therefore, in this study, we investigated the mechanistic action of PMA in prostate cancer cells with regard to AR. We showed that PMA decreased E2F1 as well as AR expression in androgen-dependent prostate cancer LNCaP cells. Furthermore, PMA activated JNK and p53 signaling, resulting in the induction of cellular apoptosis. In LNCaP cells, androgen deprivation and a novel anti-androgen enzalutamide (MDV3100) augmented cellular apoptosis induced by PMA. Moreover, castration-resistant prostate cancer (CRPC) C4-2 cells were more sensitive to PMA compared with LNCaP cells and were sensitized to PMA by enzalutamide. Finally, the expression of PKC, E2F1, and AR was diminished in PMA-resistant cells, indicating that the gain of independence from PKC, E2F1, and AR functions leads to PMA resistance. In conclusion, PMA exerted its anti-cancer effects via the activation of pro-apoptotic JNK/p53 and inhibition of pro-proliferative E2F1/AR in prostate cancer cells including CRPC cells. The therapeutic effects of PMA were augmented by androgen deletion and enzalutamide in androgen-dependent prostate cancer cells, as well as by enzalutamide in castration-resistant cells. Taken together, PMA derivatives may be promising therapeutic agents for treating prostate cancer patients including CRPC patients., (© 2014 Society for Endocrinology.)
- Published
- 2014
- Full Text
- View/download PDF
37. Effects of Ang II receptor blocker irbesartan on adipose tissue function in mice with metabolic disorders.
- Author
-
Maeda A, Tamura K, Wakui H, Ohsawa M, Azushima K, Uneda K, Kobayashi R, Tsurumi-Ikeya Y, Kanaoka T, Dejima T, Ohki K, Haku S, Yamashita A, and Umemura S
- Subjects
- Adaptor Proteins, Signal Transducing biosynthesis, Animals, Blood Pressure drug effects, Body Weight drug effects, Humans, Irbesartan, Leptin biosynthesis, Mice, Obesity genetics, Obesity pathology, Receptor, Angiotensin, Type 1 metabolism, Signal Transduction drug effects, Adipose Tissue drug effects, Angiotensin II Type 1 Receptor Blockers administration & dosage, Biphenyl Compounds administration & dosage, Obesity drug therapy, Receptor, Angiotensin, Type 1 genetics, Tetrazoles administration & dosage
- Abstract
Recent studies indicate that the functional renin-angiotensin system (RAS) exists in the adipose tissue. The adipose tissue RAS is proposed in the pathophysiology of metabolic disorders. In the present study, we examined therapeutic effects of irbesartan, an angiotensin II (Ang II) type 1 receptor (AT1R)-specific blocker, in genetically obese diabetic KKAy mice, a model of human metabolic disorders without any dietary loading, with our focus on the analysis on possible effect of irbesartan on the adipose tissue. The treatment with irbesartan significantly lowered systolic blood pressure with a concomitant decrease in body weight in KKAy mice. In addition, irbesartan significantly decreased the adipose leptin mRNA expression and tended to decrease IL-6 mRNA expression in the adipose tissue of KKAy mice. Furthermore irbesartan preserved the adipose gene expression of AT1R-associated protein (ATRAP), an endogenous inhibitory molecule of tissue AT1R signaling, with a concomitant tendency of up-regulation of adipose tissue ATRAP/AT1R ratio. Collectively, these results suggest that the irbesartan-induced beneficial suppressive effect on the leptin-IL-6 axis in the adipose tissue in KKAy mice is partly mediated by a trend of up-regulation of the adipose ATRAP/AT1R ratio as one of pleiotropic effects of irbesartan.
- Published
- 2014
- Full Text
- View/download PDF
38. Effects of single pill-based combination therapy of amlodipine and atorvastatin on within-visit blood pressure variability and parameters of renal and vascular function in hypertensive patients with chronic kidney disease.
- Author
-
Azushima K, Uneda K, Tamura K, Wakui H, Ohsawa M, Kobayashi R, Dejima T, Kanaoka T, Maeda A, Toya Y, and Umemura S
- Subjects
- Aged, Amlodipine pharmacology, Antihypertensive Agents pharmacology, Atorvastatin, Biomarkers metabolism, Capsules, Drug Therapy, Combination, Female, Glucose metabolism, Heptanoic Acids pharmacology, Humans, Hypertension complications, Hypertension physiopathology, Inflammation pathology, Kidney drug effects, Kidney Function Tests, Lipid Metabolism drug effects, Male, Multivariate Analysis, Oxidative Stress drug effects, Pyrroles pharmacology, Regression Analysis, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic physiopathology, Amlodipine therapeutic use, Antihypertensive Agents therapeutic use, Blood Pressure drug effects, Heptanoic Acids therapeutic use, Hypertension drug therapy, Kidney physiopathology, Pyrroles therapeutic use, Renal Insufficiency, Chronic drug therapy
- Abstract
Both strict blood pressure (BP) control and improvements in BP profile such as BP variability are important for suppression of renal deterioration and cardiovascular complication in hypertension and chronic kidney disease (CKD). In the present study, we examined the beneficial effects of the single pill-based combination therapy of amlodipine and atorvastatin on achievement of the target BP and clinic BP profile, as well as markers of vascular and renal damages in twenty hypertensive CKD patients. The combination therapy with amlodipine and atorvastatin for 16 weeks significantly decreased clinic BP, and achievement of target BP control was attained in an average of 45% after the combination therapy in spite of the presence of no achievement at baseline. In addition, the combination therapy significantly decreased the within-visit BP variability. With respect to the effects on renal damage markers, combination therapy with amlodipine and atorvastatin for 16 weeks significantly decreased albuminuria (urine albumin-to-creatinine ratio, 1034 ± 1480 versus 733 ± 1218 mg/g-Cr, P < 0.05) without decline in estimated glomerular filtration rate. Concerning parameters of vascular function, the combination therapy significantly improved both brachial-ankle pulse wave velocity (baPWV) and central systolic BP (cSBP) (baPWV, 1903 ± 353 versus 1786 ± 382 cm/s, P < 0.05; cSBP, 148 ± 19 versus 129 ± 23 mmHg, P < 0.01). Collectively, these results suggest that the combination therapy with amlodipine and atorvastatin may exert additional beneficial effects on renal and vascular damages as well as BP profile in addition to BP lowering in hypertension with CKD.
- Published
- 2014
- Full Text
- View/download PDF
39. A C-type lectin receptor pathway is responsible for the pathogenesis of acute cyclophosphamide-induced cystitis in mice.
- Author
-
Dejima T, Shibata K, Yamada H, Takeuchi A, Hara H, Eto M, Naito S, and Yoshikai Y
- Subjects
- Adaptor Proteins, Signal Transducing genetics, Adaptor Proteins, Signal Transducing immunology, Animals, CARD Signaling Adaptor Proteins, Cystitis pathology, Cytokines metabolism, Female, Mice, Mice, Inbred C57BL, Mice, Knockout, Neutrophils immunology, Receptors, IgG genetics, Receptors, IgG immunology, T-Lymphocytes immunology, Time Factors, Cyclophosphamide toxicity, Cystitis chemically induced, Lectins, C-Type metabolism, Signal Transduction
- Abstract
Hemorrhagic cystitis often arises after cyclophosphamide (CYP) administration. As yet, however, the mechanism involved in its pathogenesis is unknown. In this study, it was found that the Fc receptor γ chain (FcRγ)- caspase recruitment domain-containing protein 9 (CARD9)-dependent pathway rather than the myeloid differentiation primary response gene 88 (MyD88)-dependent pathway is involved in the pathogenesis of acute CYP-induced cystitis in mice. Rapid and transient production of interleukin (IL)-6 and IL-1β was detected in the bladder at 4 hr, preceding IL-23 and IL-17A production and an influx of neutrophils, which reached a peak at 24 hr after injection. As assessed by weight, edema and neutrophil infiltration, cystitis was significantly attenuated in CARD9 knockout (KO) and FcRγKO mice, this attenuation being accompanied by impaired production of IL-1β, IL-6, IL-23 and IL-17A. The major source of IL-17A is the vesical γδ T cell population: IL-17AKO, CδKO and Tyk2KO mice showed little IL-17A production and reduced neutrophil infiltration in the bladder after CYP injection. These results suggest that FcRγ-CARD9-dependent production of proinflammatory cytokines such as IL-1β, IL-6, and IL-23 and the subsequent activation of IL-17A-producing γδ T cells are at least partly involved in the pathogenesis of acute CYP-induced cystitis in mice., (© 2013 The Societies and Wiley Publishing Asia Pty Ltd.)
- Published
- 2013
- Full Text
- View/download PDF
40. Activation of angiotensin II type 1 receptor-associated protein exerts an inhibitory effect on vascular hypertrophy and oxidative stress in angiotensin II-mediated hypertension.
- Author
-
Wakui H, Dejima T, Tamura K, Uneda K, Azuma K, Maeda A, Ohsawa M, Kanaoka T, Azushima K, Kobayashi R, Matsuda M, Yamashita A, and Umemura S
- Subjects
- Adaptor Proteins, Signal Transducing genetics, Aldehydes metabolism, Animals, Aorta pathology, Cells, Cultured, Cytochrome b Group metabolism, Disease Models, Animal, Hypertension chemically induced, Hypertension genetics, Hypertension pathology, Hypertension physiopathology, Hypertrophy, JNK Mitogen-Activated Protein Kinases metabolism, Mice, Mice, Inbred C57BL, Mice, Transgenic, NADPH Oxidase 4, NADPH Oxidases metabolism, Rats, Sprague-Dawley, Reactive Oxygen Species metabolism, Signal Transduction, Time Factors, Transfection, p38 Mitogen-Activated Protein Kinases metabolism, Adaptor Proteins, Signal Transducing metabolism, Angiotensin II, Aorta metabolism, Hypertension metabolism, Oxidative Stress
- Abstract
Aims: Activation of tissue angiotensin II (Ang II) type 1 receptor (AT1R) plays an important role in the development of vascular remodelling. We have shown that the AT1R-associated protein (ATRAP/Agtrap), a specific binding protein of AT1R, functions as an endogenous inhibitor to prevent pathological activation of the tissue renin-angiotensin system. In this study, we investigated the effects of ATRAP on Ang II-induced vascular remodelling., Methods and Results: Transgenic (Tg) mice with a pattern of aortic vascular-dominant overexpression of ATRAP were obtained, and Ang II or vehicle was continuously infused into Tg and wild-type (Wt) mice via an osmotic minipump for 14 days. Although blood pressure of Ang II-infused Tg mice was comparable with that of Ang II-infused Wt mice, the Ang II-mediated development of aortic vascular hypertrophy was partially inhibited in Tg mice compared with Wt mice. In addition, Ang II-mediated up-regulation of vascular Nox4 and p22(phox), NADPH oxidase components, and 4-HNE, a marker of reactive oxygen species (ROS) generation, was significantly suppressed in Tg mice, with a concomitant inhibition of activation of aortic vascular p38MAPK and JNK by Ang II. This protection afforded by vascular ATRAP against Ang II-induced activation of NADPH oxidase is supported by in vitro experimental data using adenoviral transfer of recombinant ATRAP., Conclusion: These results indicate that activation of aortic vascular ATRAP partially inhibits the Nox4/p22(phox)-ROS-p38MAPK/JNK pathway and pathological aortic hypertrophy provoked by Ang II-mediated hypertension, thereby suggesting ATRAP as a novel receptor-binding modulator of vascular pathophysiology.
- Published
- 2013
- Full Text
- View/download PDF
41. Bofu-tsu-shosan, an oriental herbal medicine, exerts a combinatorial favorable metabolic modulation including antihypertensive effect on a mouse model of human metabolic disorders with visceral obesity.
- Author
-
Azushima K, Tamura K, Wakui H, Maeda A, Ohsawa M, Uneda K, Kobayashi R, Kanaoka T, Dejima T, Fujikawa T, Yamashita A, Toya Y, and Umemura S
- Subjects
- Animals, Blood Pressure drug effects, Disease Models, Animal, Humans, Ion Channels metabolism, Metabolic Diseases metabolism, Mice, Mitochondrial Proteins metabolism, Obesity, Abdominal metabolism, Uncoupling Protein 1, Drugs, Chinese Herbal therapeutic use, Herbal Medicine methods, Metabolic Diseases drug therapy, Obesity, Abdominal drug therapy
- Abstract
Accumulating evidence indicates that metabolic dysfunction with visceral obesity is a major medical problem associated with the development of hypertension, type 2 diabetes (T2DM) and dyslipidemia, and ultimately severe cardiovascular and renal disease. Therefore, an effective anti-obesity treatment with a concomitant improvement in metabolic profile is important for the treatment of metabolic dysfunction with visceral obesity. Bofu-tsu-shosan (BOF) is one of oriental herbal medicine and is clinically available to treat obesity in Japan. Although BOF is a candidate as a novel therapeutic strategy to improve metabolic dysfunction with obesity, the mechanism of its beneficial effect is not fully elucidated. Here, we investigated mechanism of therapeutic effects of BOF on KKAy mice, a model of human metabolic disorders with obesity. Chronic treatment of KKAy mice with BOF persistently decreased food intake, body weight gain, low-density lipoprotein cholesterol and systolic blood pressure. In addition, both tissue weight and cell size of white adipose tissue (WAT) were decreased, with concomitant increases in the expression of adiponectin and peroxisome proliferator-activated receptors genes in WAT as well as the circulating adiponectin level by BOF treatment. Furthermore, gene expression of uncoupling protein-1, a thermogenesis factor, in brown adipose tissue and rectal temperature were both elevated by BOF. Intriguingly, plasma acylated-ghrelin, an active form of orexigenic hormone, and short-term food intake were significantly decreased by single bolus administration of BOF. These results indicate that BOF exerts a combinatorial favorable metabolic modulation including antihypertensive effect, at least partially, via its beneficial effect on adipose tissue function and its appetite-inhibitory property through suppression on the ghrelin system.
- Published
- 2013
- Full Text
- View/download PDF
42. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
- Author
-
Shiota M, Kashiwagi E, Yokomizo A, Takeuchi A, Dejima T, Song Y, Tatsugami K, Inokuchi J, Uchiumi T, and Naito S
- Subjects
- Antineoplastic Agents metabolism, Antineoplastic Agents therapeutic use, Cell Line, Tumor, Docetaxel, Drug Resistance, Neoplasm drug effects, Humans, Male, Nuclear Proteins genetics, Orchiectomy, Prostatic Neoplasms drug therapy, Prostatic Neoplasms genetics, Taxoids therapeutic use, Twist-Related Protein 1 genetics, Y-Box-Binding Protein 1 genetics, Drug Resistance, Neoplasm physiology, Nuclear Proteins metabolism, Prostatic Neoplasms metabolism, Receptors, Androgen metabolism, Taxoids metabolism, Twist-Related Protein 1 metabolism, Y-Box-Binding Protein 1 metabolism
- Abstract
Background: Taxanes, including docetaxel, are currently the only cytotoxic chemotherapeutic agents proven to confer survival benefit in patients with castration-resistant prostate cancer (CRPC). However, the merits of taxanes remain modest, and efforts are needed to improve their therapeutic efficacy., Methods: We evaluated the sensitivity of prostate cancer cells to various agents using cytotoxicity assays. Gene and protein expression levels were evaluated by quantitative real-time polymerase chain reaction and Western blotting analysis, respectively., Results: Hydrogen peroxide-resistant and castration-resistant cells that overexpressed Twist1 and Y-box binding protein-1 (YB-1) were cross-resistant to cytotoxic agents, including docetaxel. Twist1 regulated YB-1 expression in prostate cancer cells, supported by the induction of Twist1 and YB-1 by transforming-growth factor-β, which is critical for taxane resistance. Twist1 and/or YB-1 were activated in docetaxel-resistant prostate cancer cells, and YB-1 was activated by docetaxel treatment. Conversely, Twist1 and YB-1 knockdown sensitized prostate cancer cells to cytotoxic agents, including docetaxel. In addition, androgen receptor (AR) knockdown increased cellular sensitivity to docetaxel, though AR expression in docetaxel-resistant LNCaP cells was paradoxically lower than in parental cells. Intriguingly, androgen deprivation treatment was more effective in docetaxel-resistant LNCaP cells compared with parental cells., Conclusions: Twist1/YB-1 and AR signaling promote docetaxel resistance in CRPC cells. However, docetaxel-resistant cells were collaterally sensitive to androgen deprivation because of down-regulation of AR expression, suggesting that the therapeutic effect of initial taxane treatment in hormone-naïve prostate cancer may be superior to that of salvage taxane treatment in CRPC., (Copyright © 2013 Wiley Periodicals, Inc.)
- Published
- 2013
- Full Text
- View/download PDF
43. Angiotensin receptor-binding protein ATRAP/Agtrap inhibits metabolic dysfunction with visceral obesity.
- Author
-
Maeda A, Tamura K, Wakui H, Dejima T, Ohsawa M, Azushima K, Kanaoka T, Uneda K, Matsuda M, Yamashita A, Miyazaki N, Yatsu K, Hirawa N, Toya Y, and Umemura S
- Subjects
- Adaptor Proteins, Signal Transducing deficiency, Adaptor Proteins, Signal Transducing genetics, Adiposity, Adult, Animals, Biomarkers blood, Blood Pressure, Case-Control Studies, Diet, High-Fat, Disease Models, Animal, Dyslipidemias metabolism, Dyslipidemias physiopathology, Female, Genotype, Homozygote, Humans, Hypertension metabolism, Hypertension physiopathology, Hypertrophy, Insulin Resistance, Intra-Abdominal Fat pathology, Intra-Abdominal Fat physiopathology, Intra-Abdominal Fat transplantation, Male, Metabolic Syndrome genetics, Metabolic Syndrome physiopathology, Metabolic Syndrome prevention & control, Mice, Mice, Inbred C57BL, Mice, Knockout, Mice, Transgenic, Middle Aged, Obesity, Abdominal genetics, Obesity, Abdominal physiopathology, Panniculitis metabolism, Panniculitis physiopathology, Phenotype, Receptor, Angiotensin, Type 1 genetics, Receptor, Angiotensin, Type 1 metabolism, Time Factors, Young Adult, Adaptor Proteins, Signal Transducing metabolism, Intra-Abdominal Fat metabolism, Metabolic Syndrome metabolism, Obesity, Abdominal metabolism
- Abstract
Background: Metabolic disorders with visceral obesity have become a major medical problem associated with the development of hypertension, type 2 diabetes, and dyslipidemia and, ultimately, life-threatening cardiovascular and renal diseases. Adipose tissue dysfunction has been proposed as the cause of visceral obesity-related metabolic disorders, moving the tissue toward a proinflammatory phenotype., Methods and Results: Here we first report that adipose tissues from patients and mice with metabolic disorders exhibit decreased expression of ATRAP/Agtrap, which is a specific binding modulator of the angiotensin II type 1 receptor, despite its abundant expression in adipose tissues from normal human and control mice. Subsequently, to examine a functional role of ATRAP in the pathophysiology of metabolic disorders, we produced homozygous ATRAP deficient (Agtrap(-/-)) mice, which exhibited largely normal physiological phenotype at baseline. Under dietary high fat loading, Agtrap(-/-) mice displayed systemic metabolic dysfunction, characterized by an increased accumulation of pad fat, hypertension, dyslipidemia, and insulin resistance, along with adipose tissue inflammation. Conversely, subcutaneous transplantation of donor fat pads overexpressing ATRAP derived from Agtrap transgenic mice to Agtrap(-/-) recipient mice improved the systemic metabolic dysfunction., Conclusions: These results demonstrate that Agtrap(-/-) mice are an effective model of metabolic disorders with visceral obesity and constitute evidence that ATRAP plays a protective role against insulin resistance, suggesting a new therapeutic target in metabolic disorders. Identification of ATRAP as a novel receptor binding modulator of adipose tissue inflammation not only has cardiovascular significance but may have generalized implication in the regulation of tissue function.
- Published
- 2013
- Full Text
- View/download PDF
44. Addition of aliskiren to Angiotensin receptor blocker improves ambulatory blood pressure profile and cardiorenal function better than addition of benazepril in chronic kidney disease.
- Author
-
Ohsawa M, Tamura K, Kanaoka T, Wakui H, Maeda A, Dejima T, Azushima K, Uneda K, Kobayashi R, Tsurumi-Ikeya Y, Toya Y, Fujikawa T, and Umemura S
- Subjects
- Aged, Albuminuria drug therapy, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Blood Pressure drug effects, Cardio-Renal Syndrome drug therapy, Female, Heart Function Tests drug effects, Heart Rate drug effects, Humans, Hypertrophy, Left Ventricular drug therapy, Kidney Function Tests, Male, Oxidative Stress drug effects, Amides therapeutic use, Angiotensin Receptor Antagonists therapeutic use, Antihypertensive Agents therapeutic use, Benzazepines therapeutic use, Fumarates therapeutic use, Renal Insufficiency, Chronic drug therapy
- Abstract
An altered ambulatory blood pressure (BP) and heart rate (HR) profile is related to chronic kidney disease (CKD) and cardiorenal syndrome. In this study, we examined the effects of aliskiren, when added to angiotensin II type 1 receptor blockers, on ambulatory BP and cardiorenal function in CKD. Thirty-six hypertensive CKD patients were randomly assigned to the aliskiren add-on group (n = 18) or the benazepril add-on group (n = 18). Ambulatory BP and cardiorenal function parameters were measured at baseline and 24 weeks after treatment. Compared with the benazepril group, nighttime systolic BP variability in the aliskiren group was lower after treatment. Albuminuria was decreased in the aliskiren group, but not in the benazepril group. In addition, left ventricular mass index (LVMI) was significantly lower in the aliskiren group than in the benazepril group after treatment. In the aliskiren group, multivariate linear regression analysis showed an association between changes in albuminuria and changes in nighttime systolic BP. Furthermore, there were associations between changes in LVMI and changes in daytime HR variability, as well as between changes in LVMI and changes in plasma aldosterone concentration. These results suggest that aliskiren add-on therapy may be beneficial for suppression of renal deterioration and pathological cardiac remodeling through an improvement that is effected in ambulatory BP and HR profiles.
- Published
- 2013
- Full Text
- View/download PDF
45. YB-1 suppression induces STAT3 proteolysis and sensitizes renal cancer to interferon-α.
- Author
-
Takeuchi A, Shiota M, Tatsugami K, Yokomizo A, Kuroiwa K, Dejima T, Tanaka S, Itsumi M, Eto M, and Naito S
- Subjects
- Animals, Carcinoma, Renal Cell pathology, Cell Cycle Checkpoints drug effects, Cell Line, Tumor, Cell Proliferation drug effects, Female, Gene Knockdown Techniques, Humans, Interferon-alpha pharmacology, Kidney Neoplasms pathology, Mice, Mice, Inbred BALB C, Mice, Nude, Proteolysis, STAT3 Transcription Factor antagonists & inhibitors, STAT3 Transcription Factor genetics, Transplantation, Heterologous, Tumor Cells, Cultured, Y-Box-Binding Protein 1 pharmacology, Carcinoma, Renal Cell metabolism, Carcinoma, Renal Cell therapy, Interferon-alpha therapeutic use, Kidney Neoplasms metabolism, Kidney Neoplasms therapy, STAT3 Transcription Factor metabolism, Y-Box-Binding Protein 1 antagonists & inhibitors
- Abstract
Renal cell carcinoma (RCC) accounts for 80-95 % of kidney tumors, and approximately 30 % of RCC patients have metastatic disease at diagnosis. Conventional chemotherapy is not effective in patients with metastatic RCC (MRCC); therefore, immunotherapy with interferon-α (IFN-α) has been employed to improve survival. However, the response rate of MRCC to IFN-α therapy is low. We previously reported that a signal transducer and activator 3 (STAT3) polymorphism was a useful diagnostic marker to predict the response to IFN-α therapy in patients with MRCC. Therefore, we hypothesized the inhibition of STAT3 in the addition of IFN-α therapy might be useful. Moreover, the blockage of STAT3 itself has been reported to enhance the antitumor effects. However, because IFN-α is thought to elicit its therapeutic effect via enhancement of an antitumor immune response mediated by lymphocytes that can be activated by IFN-α administrations, it is probable that the suppression of STAT3 in vivo relates to autoimmune disorders. In the present study, we found Y-box binding protein-1 (YB-1) was poorly expressed in T lymphocytes, as compared with cancer tissues. YB-1 was reported to have an important effect on the STAT3 pathway. Suppression of STAT3 by YB-1 inhibition did not seem to enhance the potential risk for autoimmune disorders. Moreover, we found sensitivity to IFN-α was increased by YB-1 suppression, and this suppression did not down-regulate IFN-α activation of T lymphocytes.
- Published
- 2013
- Full Text
- View/download PDF
46. The physiology and pathophysiology of a novel angiotensin receptor-binding protein ATRAP/Agtrap.
- Author
-
Tamura K, Wakui H, Maeda A, Dejima T, Ohsawa M, Azushima K, Kanaoka T, Haku S, Uneda K, Masuda S, Azuma K, Shigenaga A, Koide Y, Tsurumi-Ikeya Y, Matsuda M, Toya Y, Tokita Y, Yamashita A, and Umemura S
- Subjects
- Adaptor Proteins, Signal Transducing analysis, Adaptor Proteins, Signal Transducing chemistry, Adaptor Proteins, Signal Transducing genetics, Animals, Cells, Cultured, Gene Expression Regulation, Humans, Protein Structure, Tertiary, Receptor, Angiotensin, Type 1 physiology, Adaptor Proteins, Signal Transducing physiology
- Abstract
The Ang II type 1 receptor (AT1R)-associated protein (ATRAP/Agtrap) is a molecule specifically interacting with the carboxyl- terminal domain of AT1R. The results of in vitro studies showed that ATRAP suppresses Ang II-mediated pathological responses in cardiovascular cells by promoting AT1R internalization. With respect to the tissue distribution and regulation of ATRAP expression in vivo, ATRAP is broadly expressed in many tissues as is AT1R. Accumulating evidence indicates that a tissue-specific regulatory balancing of ATRAP and AT1R expression may be involved in the modulation of AT1R signaling at local tissue sites and also in the pathophysiology of hypertension and its associated end-organ injury. Furthermore, the activation of ATRAP in transgenic-models inhibited inflammatory vascular remodeling and cardiac hypertrophy in response to Ang II stimulation. These results suggest the clinical potential benefit of an ATRAP activation strategy in the treatment of hypertension and related organ injury.
- Published
- 2013
- Full Text
- View/download PDF
47. An increase in perfusion pressure and activation of the renin-angiotensin system in the pathogenesis of hypertension and injury: strain vessels and the cerebrovascular-renal connection.
- Author
-
Tamura K, Maeda A, Uneda K, Wakui H, Dejima T, Mitsuhashi H, Yamaguchi S, Tsurumi-Ikeya Y, Tokita Y, and Umemura S
- Subjects
- Adaptor Proteins, Signal Transducing physiology, Angiotensin II physiology, Animals, Blood Pressure, Humans, Rats, Renal Insufficiency, Chronic complications, Cerebrovascular Circulation, Hypertension etiology, Kidney blood supply, Renal Circulation, Renin-Angiotensin System physiology
- Published
- 2012
- Full Text
- View/download PDF
48. Effects of aliskiren-based therapy on ambulatory blood pressure profile, central hemodynamics, and arterial stiffness in nondiabetic mild to moderate hypertensive patients.
- Author
-
Kanaoka T, Tamura K, Ohsawa M, Wakui H, Maeda A, Dejima T, Azushima K, Haku S, Mitsuhashi H, Yanagi M, Oshikawa J, Uneda K, Aoki K, Fujikawa T, Toya Y, Uchino K, and Umemura S
- Subjects
- Aged, Amides therapeutic use, Antihypertensive Agents pharmacology, Antihypertensive Agents therapeutic use, Blood Pressure physiology, Blood Pressure Monitoring, Ambulatory, Dose-Response Relationship, Drug, Female, Fumarates therapeutic use, Hemodynamics physiology, Humans, Hypertension drug therapy, Hypertension ethnology, Japan, Male, Middle Aged, Prospective Studies, Renin-Angiotensin System drug effects, Renin-Angiotensin System physiology, Retrospective Studies, Treatment Outcome, Vascular Stiffness physiology, Amides pharmacology, Blood Pressure drug effects, Fumarates pharmacology, Hemodynamics drug effects, Hypertension physiopathology, Severity of Illness Index, Vascular Stiffness drug effects
- Abstract
Aliskiren is a direct renin inhibitor that exerts its effect at the rate-limiting step of the renin-angiotensin system. This study was performed to examine the beneficial effects of aliskiren-based antihypertensive therapy on the ambulatory blood pressure (BP) profile, central hemodybamics, and arterial stiffness in untreated Japanese patients with mild to moderate hypertension. Twenty-one Japanese nondiabetic patients with untreated mild to moderate essential hypertension were initially given aliskiren once daily at 150 mg, and the dose was titrated up to 300 mg as needed. After 12 weeks of aliskiren-based therapy, the clinic, ambulatory, and central BP values as well as brachial-ankle pulse wave velocity (baPWV) were all significantly decreased compared with baseline (clinic systolic BP, 151 ± 11 mm Hg vs 132 ± 11 mm Hg; clinic diastolic BP, 91 ± 13 mm Hg vs 82 ± 9 mm Hg; 24-hour systolic BP, 144 ± 12 mm Hg vs 133 ± 11 mm Hg; 24-hour diastolic BP, 88 ± 8 mm Hg vs 81 ± 9 mm Hg; central BP, 162 ± 16 mm Hg vs 148 ± 14 mm Hg; baPWV, 1625 ± 245 cm/s vs 1495 ± 199 cm/s; P<.05). These results show that aliskiren, as a first-line regimen, improves the ambulatory BP profile and may have protective vascular effects in Japanese nondiabetic patients with untreated mild to moderate essential hypertension., (© 2012 Wiley Periodicals, Inc.)
- Published
- 2012
- Full Text
- View/download PDF
49. Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).
- Author
-
Maeda A, Tamura K, Kanaoka T, Ohsawa M, Haku S, Azushima K, Dejima T, Wakui H, Yanagi M, Okano Y, Fujikawa T, Toya Y, Mizushima S, Tochikubo O, and Umemura S
- Subjects
- Aged, Albuminuria drug therapy, Biphenyl Compounds, Creatinine urine, Drug Therapy, Combination, Female, Glomerular Filtration Rate drug effects, Humans, Hypertension physiopathology, Insulin Resistance, Japan, Male, Middle Aged, Amlodipine administration & dosage, Angiotensin II Type 1 Receptor Blockers administration & dosage, Antihypertensive Agents administration & dosage, Benzimidazoles administration & dosage, Blood Pressure drug effects, Calcium Channel Blockers administration & dosage, Hypertension drug therapy, Tetrazoles administration & dosage
- Abstract
Recent guidelines recommend combination antihypertensive therapy to achieve the target blood pressure (BP) and to suppress target organ damage. This study aimed to examine the beneficial effects of combination therapy with candesartan and amlodipine on BP control and markers of target organ function in Japanese essential hypertensive patients (N = 20) who did not achieve the target BP level during the monotherapy period with either candesartan or amlodipine. After the monotherapy period, for patients already being treated with amlodipine, a once-daily 8 mg dose of candesartan was added on during the combination therapy period (angiotensin II receptor blocker [ARB] add-on group, N = 10), and a once-daily 5 mg dose of amlodipine was added on for those already being treated with candesartan (calcium channel blocker [CCB] add-on group, N = 10). Combination therapy with candesartan and amlodipine for 12 weeks significantly decreased clinic and home systolic blood pressure (SBP) and diastolic blood pressure (DBP). In addition, the combination therapy was able to significantly reduce urine albumin excretion without decrease in estimated glomerular filtration ratio and resulted in significant improvements in brachial-ankle pulse wave velocity, central SBP, and insulin sensitivity. Furthermore, the CCB add-on group showed a significantly greater decrease in clinic and home DBP than the ARB add-on group. The calcium channel blocker add-on group also exhibited better improvements in vascular functional parameters than the ARB add-on group. These results suggest that combination therapy with candesartan and amlodipine is an efficient therapeutic strategy for hypertension with pleiotropic benefits.
- Published
- 2012
- Full Text
- View/download PDF
50. Relationship of ambulatory blood pressure and the heart rate profile with renal function parameters in hypertensive patients with chronic kidney disease.
- Author
-
Kanaoka T, Tamura K, Ohsawa M, Yanagi M, Haku S, Wakui H, Maeda A, Dejima T, Azushima K, Mitsuhashi H, Okano Y, Fujikawa T, Toya Y, Mizushima S, Tochikubo O, and Umemura S
- Subjects
- Aged, Albuminuria complications, Albuminuria physiopathology, Ankle Brachial Index, Blood Pressure, Blood Pressure Monitoring, Ambulatory, Cross-Sectional Studies, Female, Glomerular Filtration Rate, Heart Rate, Humans, Hypertension, Renal complications, Kidney Failure, Chronic complications, Male, Middle Aged, Renal Insufficiency, Chronic complications, Vascular Stiffness, Hypertension, Renal physiopathology, Kidney Failure, Chronic physiopathology, Renal Insufficiency, Chronic physiopathology
- Abstract
Strict blood pressure (BP) control is reportedly important for the management of hypertensive patients with chronic kidney disease (CKD). The purpose of this cross-sectional study was to examine whether the variables of ambulatory BP and the heart rate (HR) profile, central hemodynamics, and arterial stiffness were closely related to the renal function parameters (urine albumin excretion rate [UACR] and estimated glomerular filtration rate [eGFR]) observed in 25 consecutive hospitalized hypertensive patients with CKD. There were significant positive relationships between UACR and 24-hour, daytime, and nighttime ambulatory systolic BP. In addition, there were significant negative relationships between UACR and 24-hour and daytime HR variability. The circulating B-type natriuretic peptide level and hemoglobin A1c were also positively related to UACR. With respect to eGFR, although the 24-hour and nighttime HR variability were positively associated with eGFR, the circulating pentosidine and nighttime HR had a negative relationship with eGFR. On the other hand, central hemodynamics and arterial stiffness did not exhibit any significant association with renal function parameters. These results indicate that ambulatory BP and the HR profile are closely modulated by renal function deterioration. Further studies are needed to investigate the causal relationship between ambulatory BP and the HR profile and renal function parameters in hypertensive patients with CKD.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.